Get the latest news, insights, and market updates on POAI (Predictive Oncology Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Axe Compute (NASDAQ: AGPU) Named Sponsor of the Sequire Investor Summit Puerto Rico 2026
San Juan, Puerto Rico, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axe Compute Inc. (NASDAQ: AGPU), a next-generation computing infrastructure company focused on high-performance and AI-driven solutions, announced it will serve as a sponsor of the Sequire Investor Summit Puerto Rico 2026, taking place January 20–22, 2026 at the iconic Condado Vanderbilt Hotel in San Juan. Hosted by DNA, the Sequire Investor Summit is a premier investor conference bringing together over 500 institutional and retail investo Jan 12, 2026 - $POAI
Predictive Oncology Becomes Axe Compute, Expanding Into High-Performance AI Infrastructure
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Axe Compute Inc. (NASDAQ: AGPU) (the “Company” or “Axe Compute”) today announced that it has changed its name to Axe Compute Inc., with its common stock to begin trading on Nasdaq under the ticker symbol AGPU on December 12, 2025. Axe Compute will continue to operate its AI-driven drug discovery business and plans to expand its business into high-performance enterprise AI infrastructure, addressing rising global demand for predictable, scalable compute Dec 12, 2025 - $POAI
Predictive Oncology Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
PITTSBURGH, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native utility token of the Aethir network, today announced that on December 1, 2025, the Company received a notification letter from Nasdaq notifying the Company that it regained compliance with Nasdaq's minimum stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1), Dec 2, 2025 - $POAI
Predictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset Strategy
Company to host investor conference call and webcast on Monday, November 17th, at 9:00am ESTPITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), an AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native utility token of the Aethir network, today reported financial and operating results for the quarter ended September 30, 2025, and provided a corporate update. Q3 2025 and Recent Highlights: Announ Nov 14, 2025 - $POAI
AI Arms Race Accelerates as U.S. Reclaims Strategic Edge in Defense Technology
San Francisco, Oct. 10, 2025 (GLOBE NEWSWIRE) -- SAN FRANCISCO, CA - October 10, 2025 - - The global race to dominate artificial intelligence has reached a decisive inflection point as the United States sharpens its defense innovation agenda under the Trump Administration's renewed "Peace Through Strength" strategy. Insights from the EarlyBirds AI Ecosystem Map reveal a powerful convergence of public and private investment in AI infrastructure, autonomous systems, and secure computing that is ra Oct 10, 2025 - $POAI
Predictive Oncology Announces 1-for-15 Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on September 30, 2025PITTSBURGH, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI), a leader in AI-driven drug development and discovery, today announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding shares of common stock. The reverse stock split will become effective at 12:01 a.m. on Tuesday, September 30, 2025. Predictive Oncology’s common stock will continue to be traded on Nas Sep 25, 2025 - $POAI
Predictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer Patients
Collaboration builds upon positive results utilizing Predictive Oncology’s AI platform to identify new indications for existing drugsPITTSBURGH, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug development and discovery, and Every Cure, a leading nonprofit dedicated to identifying and validating new uses for existing drugs, today announced a strategic collaboration to identify and prioritize drugs for repurposing to improve patient outcomes a Sep 4, 2025 - $POAI
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple